Enanta (NASDAQ: ENTA) awards director 20,000-share stock option grant

Rhea-AI Filing Summary

Enanta Pharmaceuticals director Bruce L. A. Carter received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $14.17 per share and expire on March 11, 2036. They become exercisable monthly in substantially equal installments over one year starting March 11, 2026, with final vesting no later than the trading day before the 2027 annual stockholders meeting. Following this grant, he holds options on 20,000 shares directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARTER BRUCE L A

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.17	03/11/2026		A		20,000		(1)	03/11/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.

	/s/ Matthew Kowalsky as attorney-in-fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ENANTA (ENTA) report for Bruce L. A. Carter?

Enanta reported that director Bruce L. A. Carter received a grant of stock options for 20,000 shares of common stock. The options were granted at an exercise price of $14.17 per share and are held directly following this award.

How many Enanta (ENTA) shares are covered by Bruce Carter’s new stock option grant?

The new stock option grant to Bruce Carter covers 20,000 shares of Enanta common stock. These options give him the right to buy that number of shares at a fixed exercise price if and when they vest and are exercised.

What is the exercise price and expiration date of Bruce Carter’s ENTA stock options?

Bruce Carter’s stock options have an exercise price of $14.17 per share and expire on March 11, 2036. This means he may choose to exercise the options at that price any time after vesting and before the expiration date.

What is the vesting schedule for Bruce Carter’s Enanta (ENTA) stock option grant?

The option will become exercisable monthly in substantially equal installments over one year starting March 11, 2026. The final monthly installment will vest no later than the nearest Nasdaq Global Select Market trading day before the 2027 annual stockholders meeting.

How many ENTA stock options does Bruce Carter hold after this Form 4 transaction?

After this reported transaction, Bruce Carter holds stock options on 20,000 shares of Enanta common stock directly. This reflects the full size of the new grant reported, with no additional option holdings shown in the summarized data.

Is Bruce L. A. Carter a director or officer of Enanta Pharmaceuticals (ENTA)?

Bruce L. A. Carter is identified as a director of Enanta Pharmaceuticals. The Form 4 indicates he is not listed as an officer and does not report status as a ten percent owner in connection with this specific option grant.